Abstract
Comparing data from WATER and WATER II trials, we found that Aquablation is effective in patients with a prostate of 30–80 cm3 and patients with a prostate of 80–150 cm3 treated for lower urinary tract symptoms due to benign prostatic hyperplasia, with comparable outcomes in both groups. Functional outcome improvements are durable and retreatment rates are low at 2 yr of follow-up.
Original language | English (US) |
---|---|
Pages (from-to) | 21-28 |
Number of pages | 8 |
Journal | European Urology Open Science |
Volume | 25 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- Aquablation
- Benign prostatic hyperplasia
- Robotics
ASJC Scopus subject areas
- Urology